GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Adicet Bio
Adicet Bio is a biotech company developing next-generation cell therapies for cancer treatment. Its stock price represents a venture bet that its platform will prove safer and more effective than existing methods. The chart reflects news from clinical trials.
Share prices of companies in the market segment - Pharma immune
Adicet Bio is a biotechnology company developing allogeneic gamma-delta T-cell-based therapies for the treatment of cancer and other diseases, aiming to create ready-to-use cell-based therapies. We have classified it in the "Pharma-Immune" segment. The chart below shows the overall dynamics in the advanced cell therapy sector.
Broad Market Index - GURU.Markets
Adicet Bio is a biotech company developing a universal ("allogeneic") cell therapy based on gamma-delta T cells for the treatment of cancer. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Adicet compares to it.
Change in the price of a company, segment, and market as a whole per day
ACET - Daily change in the company's share price Adicet Bio
Adicet Bio, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about its cell therapy clinical trials, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Pharma immune
Adicet Bio, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ACET, which focuses on cell therapy, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Adicet Bio is a biotech company working in the field of immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Adicet Bio
Adicet Bio, Inc.'s year-to-date performance is a story of developing a new generation of gamma-delta T-cell-based cell therapy. Its 12-month market cap is entirely dependent on clinical trial data. The success of its "off-the-shelf" platform could offer a new, more potent approach to treating both blood cancers and solid tumors.
Annual dynamics of market capitalization of the market segment - Pharma immune
Adicet Bio, Inc. is a biotech company developing a "off-the-shelf" cell therapy based on gamma-delta T cells. Its stock price is entirely dependent on clinical trial results. The chart reflects the enormous potential of its innovative platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adicet Bio is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Adicet Bio
Adicet Bio is a biotech company developing gamma-delta CAR T-cell therapy. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its oncology programs is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Cell therapy is one of the most science-intensive and risky segments of biotech. Its market capitalization dynamics, shown in the chart, reflect investors' faith in breakthrough cancer treatments. In this environment, dominated by clinical trial data, companies like Adicet Bio are pursuing their expensive research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adicet Bio, a biopharmaceutical company working in the field of immunotherapy, lives in a world of clinical data. Its shares rise and fall on trial news, defying overall market trends. This chart clearly demonstrates this independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Adicet Bio
Shares of Adicet Bio, a biopharmaceutical company developing gamma-delta T-cell-based cell therapy, have been experiencing extreme weekly volatility. Clinical trial data, especially when compared to existing CAR-T therapies, are causing sharp price movements.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Adicet Bio and the entire cell therapy sector are moving against a backdrop of scientific breakthroughs and investor expectations. Regulatory news and clinical trial data are creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Adicet Bio and the entire cell therapy sector are moving against a backdrop of scientific breakthroughs and investor expectations. Regulatory announcements are creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Market capitalization of the company, segment and market as a whole
ACET - Market capitalization of the company Adicet Bio
The Adicet Bio market capitalization chart represents the financial valuation of a biotech company at the forefront of gamma-delta T-cell cell therapy. It reflects investor expectations for this novel cancer treatment platform. Its speculative dynamics tell the story of how the market evaluates the potential of this new approach in immuno-oncology.
ACET - Share of the company's market capitalization Adicet Bio within the market segment - Pharma immune
Adicet Bio is a clinical-stage biotech company developing allogeneic (donor-derived) gamma-delta T-cell-based therapies for cancer treatment. Its market share reflects the potential of its unique cell platform. The chart below illustrates the market's confidence in this new generation of immunotherapy.
Market capitalization of the market segment - Pharma immune
Adicet Bio is a biopharmaceutical company developing gamma-delta T-cell-based therapies. The chart below shows the overall market capitalization of the immunopharmaceuticals sector. It reflects the search for new types of "living drugs" to fight cancer. Adicet is at the forefront of this innovative field.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cell therapy, as seen in the graph, is a cutting-edge approach to cancer treatment. Adicet Bio is developing a therapy based on gamma-delta T cells. Its capitalization is a risky bet that this approach will prove effective and safe in the fight against cancer.
Book value capitalization of the company, segment and market as a whole
ACET - Book value capitalization of the company Adicet Bio
Adicet Bio's book value is capital for gamma-delta T-cell-based cell therapy. Currently in the R&D stage, the company is using its financial assets to develop and clinically test ready-to-use drugs that could represent a new approach to cancer treatment.
ACET - Share of the company's book capitalization Adicet Bio within the market segment - Pharma immune
Adicet Bio, a cell therapy company, is building its scientific and manufacturing base. Its share of the sector's assets includes R&D centers and production facilities for its gamma-delta T-cell therapies. This provides the physical foundation for a new approach to cancer treatment.
Market segment balance sheet capitalization - Pharma immune
Adicet Bio is a cell therapy company, making its model intellectually rather than capital-intensive at its current stage. Its value lies in its platform for developing gamma-delta T cells. Compared to the overall biotech sector, its "light" balance sheet is typical of companies focused on breakthrough R&D.
Book value of all companies included in the broad market index - GURU.Markets
Adicet Bio's assets are not chemical compounds, but rather a platform for developing gamma-delta T-cell-based therapies, a powerful new weapon against cancer. The company's balance sheet reflects the value of this cutting-edge cell technology. The chart shows how much capital is invested in the next step in immuno-oncology development.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Adicet Bio
Adicet Bio is a biotech company developing cell therapy based on gamma-delta T cells. Its market capitalization is a valuation of its cutting-edge scientific platform. Investors invest in the potential to create a new generation of cancer drugs, rather than in current tangible assets.
Market to book capitalization ratio in a market segment - Pharma immune
Adicet Bio is a biotech company developing next-generation cell therapies for cancer. Its market capitalization is a pure bet on the success of its scientific platform. This chart shows the vast gap between investor expectations and the current value of its laboratory assets.
Market to book capitalization ratio for the market as a whole
Adicet Bio is a biotech company developing cell therapies for cancer. Its market capitalization is based entirely on the potential of its scientific platform. The chart demonstrates the high premium the market is paying for the hope of a breakthrough in cancer treatment, despite the company's lack of significant tangible assets.
Debts of the company, segment and market as a whole
ACET - Company debts Adicet Bio
Adicet Bio is a biotech company developing gamma-delta T-cell-based therapies for cancer treatment. Advancing this cutting-edge cell platform through clinical trials requires significant capital. This chart shows how the company uses funding to support its expensive research.
Market segment debts - Pharma immune
Adicet Bio is a biotech company specializing in cell therapy. Funding for expensive clinical trials is key. This chart shows whether the company follows the standard equity financing model or raises other forms of capital, which may indicate partnerships or the maturity of its developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Adicet Bio
Adicet Bio, a biopharmaceutical company specializing in cell therapy, invests heavily in research and development. This chart shows its reliance on debt. Debt in biotech is always a high risk: failure in clinical trials can wipe out the entire value of the development, leaving the company to fend for itself.
Market segment debt to market segment book capitalization - Pharma immune
Adicet Bio is a pioneer in the development of off-the-shelf cell therapy based on gamma-delta T cells for cancer treatment. This chart compares the debt raised for this cutting-edge research with the overall market capitalization of the immune pharmaceutical sector. It illustrates the financial risks of developing a universal cell therapy.
Debt to book value of all companies in the market
Adicet Bio is a biotech company specializing in immunotherapy development. Its operations require significant R&D investments well before revenue generation. This chart allows investors to see how the company's debt load compares to industry norms, where high debt levels can signal both creditor confidence and high risk.
P/E of the company, segment and market as a whole
P/E - Adicet Bio
This chart for Adicet Bio, a biotech company developing cell therapies, is a valuation of its innovative platform. Since the company has no commercial products, its value is based on the potential of future drugs. Share price performance is directly dependent on clinical trial results, which can either confirm or contradict investor expectations.
P/E of the market segment - Pharma immune
This chart reflects the average valuation for the speculative cell therapy sector—a benchmark for Adicet Bio. The entire sector is valued based on expectations for future breakthroughs. For investors, this benchmark reflects the overall level of faith in this technology. This provides a useful framework for assessing expectations for Adicet's developments.
P/E of the market as a whole
Adicet Bio is a biotech company developing gamma-delta T-cell-based therapy for cancer treatment. This is another innovative approach in cellular immunotherapy. The company's valuation is based on the potential of its platform. This chart shows the market's risk appetite, allowing investors to understand how this technology compares to other cell therapies and its chances of success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Adicet Bio
Adicet Bio is a biotech company developing allogeneic (donor) gamma-delta T-cell-based cell therapy for cancer treatment. This chart reflects analysts' expectations for its cutting-edge scientific platform, indicating market confidence that this approach could be a breakthrough in immuno-oncology.
%20P%2FE%20Adicet%20Bio&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Adicet-Bio&v=1772556800092 "Chart of the company's future (projected) P/E Adicet Bio")
Future (projected) P/E of the market segment - Pharma immune
Adicet Bio is a biotech company developing gamma-delta T-cell-based therapies for cancer treatment. This chart shows how its profitability expectations compare to the cell therapy sector. It reflects how highly investors value its unique platform, which may offer advantages over existing CAR-T therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772556800123 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Adicet Bio is a clinical-stage biotech company developing gamma-delta T-cell-based therapies for the treatment of cancer. This chart reflects overall risk appetite. For Adicet, clinical trial results are fundamental. A positive market environment helps with funding, but cannot replace a scientific breakthrough.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772556800150 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Adicet Bio
Adicet Bio is a clinical-stage biotechnology company developing allogeneic (donor-derived) gamma-delta T-cell-based therapy for cancer treatment. This chart shows the financial impact of this cutting-edge cellular immunotherapy. Current results reflect significant investment in research to create universal anti-cancer drugs.
Profit of companies in the market segment - Pharma immune
Adicet Bio is a biotech company developing allogeneic (donor) gamma-delta T-cell-based therapy for cancer treatment. This is a cutting-edge approach in cellular immunotherapy. This chart shows the financial pulse of the immunopharmaceutical sector, reflecting the market's confidence in the commercial potential of new cancer treatment platforms.
Overall market profit
Adicet Bio is a biotech company developing cell therapy based on gamma-delta T cells. Its success depends on scientific breakthroughs, not GDP. There is always a need for cancer treatment. However, a strong economy and a rising stock market, as reflected in this chart, create a favorable environment for attracting capital for expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Adicet Bio
Adicet Bio is a biotechnology company developing a novel cell therapy for cancer based on gamma-delta T cells. This is a pioneering approach in immuno-oncology. This graph reflects analysts' long-term and speculative expectations regarding the clinical and commercial success of this cutting-edge technology.
%20profit%20of%20the%20company%20Adicet%20Bio&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Adicet-Bio&v=1772556800250 "Graph of future (projected) profit of the company Adicet Bio")
Future (predicted) profit of companies in the market segment - Pharma immune
Adicet Bio is a pioneer in the development of "off-the-shelf" (allogeneic) gamma-delta T-cell-based cell therapies for cancer treatment. This chart shows forecasts for the cellular immunotherapy sector. Adicet's future profitability depends on the success of its unique platform, which could offer a more affordable and rapid alternative to personalized cell therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772556800429 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Adicet Bio is a biotech company developing gamma-delta T-cell-based immunotherapy for cancer treatment. Its market cap and ability to fund research depend on investor sentiment in the tech sector. This chart, which displays general profit expectations, shows how willing the market is to invest in cutting-edge, yet risky, research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772556800500 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Adicet Bio
Adicet Bio is a biotech company developing gamma-delta T-cell-based therapies for cancer treatment. This chart reflects the high expectations of investors. The company's valuation is based not on current sales, but on the potential of its innovative cell therapy platform, which could become a breakthrough in oncology.
P/S market segment - Pharma immune
Adicet Bio is a biopharmaceutical company developing allogeneic (donor-derived) gamma-delta T-cell-based therapy for cancer treatment. This is a cutting-edge approach in cellular immunotherapy. This chart reflects the average biotech valuation, helping to understand how investors value the potential of this innovative platform compared to other cell technologies.
P/S of the market as a whole
Adicet Bio is a biotech company developing gamma-delta T-cell-based therapies for the treatment of cancer. This innovative approach to immuno-oncology is being pursued. This revenue valuation indicator emphasizes that Adicet's value is determined not by current revenue, but by investors' belief in the breakthrough potential of its scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Adicet Bio
Adicet Bio is a biopharmaceutical company developing allogeneic (donor-derived) gamma-delta T-cell-based therapies for cancer treatment. This chart reflects investors' confidence in the potential of this cutting-edge platform. The valuation is based on future revenues from the "off-the-shelf" cell-based therapies, should they be successfully clinically developed.
%20P%2FS%20Adicet%20Bio&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Adicet-Bio&v=1772556800701 "The graph of the company's future (projected) P/S Adicet Bio")
Future (projected) P/S of the market segment - Pharma immune
Adicet Bio is developing gamma-delta T-cell-based therapy for the treatment of cancer. This chart compares the company's future revenue expectations with its industry. It reflects the market's assessment of the potential of this new cell therapy platform and investor confidence in the success of its clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772556800707 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Adicet Bio is a biotech company developing allogeneic gamma-delta T-cell-based therapy for cancer treatment. This chart shows overall revenue expectations, and Adicet is an example of a potential source. Success with its innovative platform could create a powerful new tool in the fight against cancer and open up a huge market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772556800732 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Adicet Bio
Adicet Bio is a clinical-stage biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer. Its revenue, shown in this chart, is generated not from sales but from payments from strategic partners, such as Regeneron, for co-development of therapies.
Sales of companies in the market segment - Pharma immune
Adicet Bio is a biotech company developing universal (off-the-shelf) gamma-delta T-cell-based cell therapies for cancer treatment. Their approach could make cell therapy more accessible. This graph reflects the dynamics of the oncology sector, where such innovations have the potential to fundamentally change the treatment paradigm.
Overall market sales
Adicet Bio is a biotech company developing cell therapy based on gamma-delta T cells. Its future depends on successful clinical trials and raising capital. The growth in overall economic activity, reflected in this chart, is improving the investment climate. This makes it easier for companies like Adicet to secure funding for expensive research and development.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Adicet Bio
Adicet Bio is a biopharmaceutical company developing a new type of cell therapy based on gamma-delta T cells for the treatment of cancer. This technology could offer a ready-to-use, "universal" solution. This graph reflects analysts' expectations for the success of clinical trials and the potential of this cutting-edge immunotherapy.
%20sales%20of%20the%20company%20Adicet%20Bio&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Adicet-Bio&v=1772556800812 "Schedule of future (projected) sales of the company Adicet Bio")
Future (projected) sales of companies in the market segment - Pharma immune
Adicet Bio is a biotech company developing off-the-shelf cell therapies based on gamma-delta T cells for the treatment of cancer. This chart shows forecasts for the immune pharmacology sector, allowing us to assess how innovative platforms like Adicet's are shaping the future of oncology and the entire segment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772556800873 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Adicet Bio, a pioneer in cell therapy, sees this chart as an indicator of the biotech investment climate. The strong economic environment reflected here is driving an influx of venture capital and increased partnerships with big pharma, which is necessary to fund the development of their innovative cancer treatment platform.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772556800982 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Adicet Bio
Adicet Bio is a clinical-stage biotech company developing gamma-delta T-cell-based therapies for the treatment of cancer. This chart reflects the company's current phase: a phase of intensive investment in research and clinical trials. It shows how capital is being directed toward developing innovative treatments rather than generating current profits.
Market segment marginality - Pharma immune
Adicet Bio is a biotech company developing gamma-delta T-cell-based cell therapy for cancer treatment. Efficiency in this cutting-edge field means optimizing research and production costs for complex "live" drugs. This chart provides insight into how the company manages its resources compared to its competitors.
Market marginality as a whole
Adicet Bio is a biotech company developing gamma-delta T-cell-based therapies for cancer treatment. This chart shows current profitability, while Adicet is working on the next generation of cell therapy. Their financial performance reflects an investment in science that can offer new hope for patients.
Employees in the company, segment and market as a whole
Number of employees in the company Adicet Bio
Adicet Bio is at the forefront of cancer immunotherapy, developing cell-based therapies based on gamma-delta T cells. This chart shows the size of its team of scientists and clinicians. The growth of its staff directly correlates with the progress of its unique platform and the advancement of candidates into late-stage clinical trials.
Share of the company's employees Adicet Bio within the market segment - Pharma immune
Adicet Bio is a pioneer in developing gamma-delta T-cell-based therapies for cancer treatment. In this highly competitive field, scientific talent is the most important resource. This chart shows the percentage of all scientists working on this promising type of immune cell that Adicet has. This is a direct indicator of its innovative leadership and scientific potential.
Number of employees in the market segment - Pharma immune
Adicet Bio is a biotechnology company developing allogeneic (donor) gamma-delta T-cell-based therapy for cancer treatment. Its main asset is its scientific team. This chart shows the growth of its intellectual capital. The increase in staff directly correlates with progress in clinical trials and the expansion of manufacturing capabilities.
Number of employees in the market as a whole
Adicet Bio is a biotech company specializing in cell therapy. Its HR policy is determined by progress in scientific research and clinical trial results. This chart reflects the overall economic climate, but in Adicet's world, storm or calm depends on the data obtained in the lab.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Adicet Bio (ACET)
Adicet Bio is another example of a biotech company whose market capitalization is based on expectations for scientific developments. This chart clearly demonstrates how the market values its pipeline. A very high ratio per employee is a classic sign of an R&D company in the pharmaceutical industry.
%20of%20the%20company%20Adicet%20Bio%20(ACET)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Adicet-Bio-ACET&v=1772556801246 "Chart of market capitalization per employee (in thousands of dollars) of the company Adicet Bio (ACET)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Adicet Bio is a biotech company specializing in the development of gamma-delta T-cell-based cell therapy for cancer treatment. The company's value is determined solely by its scientific platform. This chart shows how highly investors value the potential of this unique technology per research employee.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772556801253 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Adicet Bio is a biotech company developing allogeneic gamma-delta T-cell-based cancer therapy. This is at the forefront of cell therapy. The chart illustrates the enormous value the market places on a small team of scientists whose work could lead to the creation of universal, "off-the-shelf" cell-based cancer treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772556801262 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Adicet Bio (ACET)
Adicet Bio is a biotech company developing gamma-delta T-cell-based therapy for cancer treatment. It's pure immuno-oncology. This graph, negative, represents the investment phase. It reflects how much capital the company is investing in each of its scientists to advance this cutting-edge cell therapy through clinical trials.
%20Chart%20Adicet%20Bio%20(ACET)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Adicet-Bio-ACET&v=1772556801268 "Company Profit Per Employee (in thousands of dollars) Chart Adicet Bio (ACET)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Adicet Bio (ACET) is a biotech company specializing in the development of "off-the-shelf" (allogeneic) gamma-delta T-cell-based therapies for oncology. This chart demonstrates the effectiveness of the R&D model. It reflects how successfully the team of scientists is advancing expensive cell therapy research, leveraging capital to create future value.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772556801296 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Adicet Bio is another biotech company specializing in cell therapy (gamma-delta T cells) for cancer treatment. Adicet's business is pure science. Its employees are scientists, not salespeople. This chart clearly demonstrates that the company is in the intensive R&D phase, where every employee is a cost center, working to develop a future multi-billion-dollar technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772556801304 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Adicet Bio (ACET)
Adicet Bio is a biotech company developing cell therapy for cancer. This graph reflects future potential during clinical trials. Significant revenue per employee will only emerge after the drug is approved, at which point it will demonstrate how a small team of scientists can change the paradigm of cancer treatment.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Adicet-Bio-ACET&v=1772556801313 "Sales chart per company employee Adicet Bio (ACET)")
Sales per employee in the market segment - Pharma immune
Adicet Bio is a biotech company developing gamma-delta T-cell-based therapies for cancer treatment. This is one of the most advanced approaches in immunotherapy. This chart shows the average revenue per employee in the sector. It serves as a benchmark for assessing the commercial potential and productivity of this complex scientific platform compared to other biotech companies.
Sales per employee for the market as a whole
Adicet Bio, Inc. (ACET) is a biotechnology company developing allogeneic (universal) gamma-delta T-cell-based therapy for the treatment of cancer. This is a cutting-edge cell therapy. The company is in the R&D stage. This chart shows the current (minimum) partnership revenue per scientist while the drugs are in clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Adicet Bio (ACET)
Adicet Bio is a biotech company working on developing a ready-to-use (allogeneic) cell therapy based on gamma-delta T cells for cancer treatment. This is a highly competitive field. The chart shows the number of investors betting that Adicet's approach will lose out to competitors or that its therapy will prove insufficiently effective or safe in the clinic.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Adicet-Bio-ACET&v=1772556801365 "Short Shares Chart for the Company Adicet Bio (ACET)")
Shares shorted by market segment - Pharma immune
Adicet Bio is a pioneer in developing in vitro gamma-delta T-cell-based cancer therapy. This chart measures the overall skepticism in the sector. Its rise indicates that investors are betting heavily against this entire therapeutic platform, considering it too risky or unviable compared to other approaches.
Shares shorted by the overall market
Adicet Bio is another biotech company working at the cutting edge of science (CAR-T therapy). This chart measures the level of fear. When it's high, investors stop believing in a "medical revolution" and demand profits. R&D funding becomes more expensive, and cash-burning companies like Adicet are the first to be hit.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Adicet Bio (ACET)
This chart for Adicet Bio is a clear barometer of biotech hopes. The company is a pioneer in cancer treatment using gamma-delta T cells. It's at the cutting edge of science. Any positive data from the lab or early-stage trials triggers a flurry of buying and "overheating" (above 70). At the same time, high development costs and the risk of clinical failure often lead to deep "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Adicet-Bio-ACET&v=1772556801428 "RSI 14 indicator chart for the company's stock Adicet Bio (ACET)")
RSI 14 Market Segment - Pharma immune
Adicet Bio (ACET) is a "CAR-T" 2.0 (gamma delta). They "engineer" a rare type of immune cell (gamma delta T) and are creating a "universal" (off-the-shelf) cancer drug. The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is ACET's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Adicet Bio (ACET) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACET (Adicet Bio)
Adicet Bio (ACET) is a biotech company developing off-the-shelf (allogeneic) gamma-delta T-cell-based cell therapies for cancer treatment. This chart shows the average target price. It reflects analysts' confidence in this advanced immunology platform and their expectations based on clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACET-Adicet-Bio&v=1772556801496 "A chart showing analyst consensus forecasts for the expected stock price. ACET (Adicet Bio)")
The difference between the consensus estimate and the actual stock price ACET (Adicet Bio)
Adicet Bio (ACET) is a biotech company developing allogeneic (donor-derived, "off-the-shelf") gamma-delta T-cell therapy for cancer. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their cell platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACET-Adicet-Bio&v=1772556801541 "A chart showing the difference between the consensus forecast and the actual stock price. ACET (Adicet Bio)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Adicet Bio is a biotech company developing off-the-shelf cell therapies (gamma-delta CAR-T) for cancer treatment. This R&D is at the cutting edge of science. This chart reflects analysts' overall expectations across the immune pharma sector. It shows whether experts believe in the future of "universal" cell therapy.
Analysts' consensus forecast for the overall market share price
Adicet Bio is a clinical-stage biotech company specializing in gamma-delta T-cell therapy. It's a risky R&D venture. This chart, which measures the market's overall risk appetite, is crucial. When optimism prevails, investors are willing to fund capital-intensive R&D projects. When pessimism rises, funding for companies like ACET becomes scarce.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Adicet Bio
Adicet Bio is a biotech company working at the cutting edge of cell therapy. They are developing allogeneic CAR-T cells using gamma-delta T cells, which they believe offer advantages over traditional alpha-beta T cells. This chart is a clear indicator of faith in their science. Its dynamics reflect the market's speculative assessment of their R&D platform and clinical trial data.
AKIMA Market Segment Index - Pharma immune
Adicet Bio (ACET) is a biotech company developing allogeneic (donor) CAR-T therapies based on gamma-delta T cells. This represents a breakthrough in cancer cell therapy. The chart shows the average index for the segment. It serves as a barometer, allowing investors to assess how market expectations for Adicet's platform compare to the average risk in the immune pharma sector.
The AKIM Index for the overall market
Adicet Bio is a biotech company developing off-the-shelf gamma-delta T-cell therapies for cancer treatment. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical to funding this cutting-edge cell therapy platform.
